CB Insights January 3, 2025
AI promises to accelerate the path from bench to bedside. Using CB Insights data, we highlight emerging markets in the preclinical phase that are ripe for pharma investments and partnerships.
This is the second report in a 3-part series on how AI is reshaping discovery, preclinical, and clinical research in drug R&D. Read part 1 on the discovery phase here.
For pharma companies, it’s critical to maximize efficiency in preclinical development — the stage after drug discovery and before clinical trials — as poor processes can mask early warning signs of drug candidates that are likely to fail.
The stakes are high: Studies show that 90% of drugs fail in clinical trials. In Phase 1 trials alone — which...
Today's Sponsors
Today's Sponsor